STAT+: In private meetings, White House works to win pharma companies’ support for drug pricing bill
Why it matters: This could reshape drug pricing, impacting patient costs and pharmaceutical industry dynamics ahead of the election.
- The White House has drafted legislative text for its drug pricing policy and is sharing it with over a dozen major pharmaceutical companies.
- The draft legislation closely aligns with the outlines of voluntary deals previously made between the administration and pharma companies.
- A key policy within the draft would allow drugs purchased with cash to be counted toward a patient’s deductible, potentially benefiting consumers.
- The Trump administration's push for drug price legislation is part of a larger effort to enact health reforms, with an increased focus on affordability during an election year.
The White House is actively engaging major pharmaceutical companies in private meetings, sharing draft legislative text for a drug pricing policy that mirrors previous voluntary agreements. This legislative push, part of the Trump administration's broader health reform agenda, aims to secure industry support for measures like allowing cash drug purchases to count towards patient deductibles, particularly as the election year emphasizes affordability.
